Top Markets
Coin of the day
Vicapsys Life Sciences, Inc. Vicapsys Life Sciences, Inc.

Vicapsys Life Sciences, Inc.

VICP
주식 순위 #25718
Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive... Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive VICAPSYN product to market, guiding it through development and commercialization. This product's intended application is within the field of transplantation, specifically for various transplant therapies and associated stem-cell uses. Additionally, the company is advancing the development of VYBRIN, a compound based on CXCL12. VYBRIN is being investigated for multiple purposes: preventing the formation of post-surgical adhesions following abdominal operations, coating implantable medical devices and other implants to inhibit fibrosis, and promoting wound healing, with a particular emphasis on diabetic ulcers. The firm, originally incorporated in 1997, transitioned its name from Phage Therapeutics International, Inc. to Vicapsys Life Sciences, Inc. in September 2017. Its operations are headquartered in Suwanee, Georgia.
주가
$1.45
마지막 동기화: 2026-08-19
시가총액
$46.94M
변동 (1일)
0.00%
변동 (1년)
-18.08%
국가
US
거래 Vicapsys Life Sciences, Inc. (VICP)

카테고리

Vicapsys Life Sciences, Inc. (VICP)의 P/S 비율
2026 기준 P/S 비율 TTM: 0
Vicapsys Life Sciences, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 0입니다. 2026년 말 기준 P/S 비율은 0였습니다.
Vicapsys Life Sciences, Inc.의 P/S 비율 기록 (2026 ~ 2026)
매년 말 P/S 비율
연도 P/S 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/S 비율
회사 P/S 비율 P/S 비율 차이 국가
10.17 -
US
10.13 -
NL
2.95 -
AU
- -
CH
11.28 -
US